Psyence Biomedical Ltd
Research Psyence Biomedical Ltd (PBM) on Bullrun: market cap USD 4.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPBM
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.85M
- Financial periodFY2026
- RevenueUSD 0
- Net income-USD 6.94M
- Free cash flow-USD 8.64M
Valuation Snapshot
latest market cap is USD 4.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 0 | -USD 6.94M | -USD 8.64M | n/a | n/a | USD 7.44M | n/a | USD 16.94M |
| FY2025 | USD 0 | USD 1.01M | -USD 3.74M | n/a | 32.76 | USD 6.14M | n/a | USD 6.72M |
| FY2024 | USD 0 | -USD 51.16M | -USD 2.95M | n/a | -14274.29 | USD 733.19K | USD 10.45M | -USD 10.97M |
| FY2023 | USD 0 | -USD 3.21M | -USD 1.59M | n/a | -940.02 | USD 1.33M | USD 733.09K | -USD 200.45K |
| FY2022 | USD 0 | -USD 1.86M | -USD 1.40M | n/a | -544.78 | USD 1.75M | n/a | USD 1.70M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 4.85M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.81M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 45.37M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 736.31M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | n/a | 7475.6 | n/a | n/a |
| 2021 | 2021-12-31 | n/a | 12295.7 | n/a | n/a |
About Psyence Biomedical Ltd
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Psyence Biomedical Ltd's market cap?
Psyence Biomedical Ltd's market capitalization is USD 4.85M.
What does Psyence Biomedical Ltd do?
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.